IMVT Shorts Drift Lower, Insiders Sell Into a 24% Monthly Slide

Immunovant has dropped 24% over the past month to $28.41, yet short sellers have been quietly trimming rather than pressing the bet, creating an unusual tension between the price action and the positioning underneath it.

Short interest runs at 10.3% of free float, a level that is genuinely elevated for a mid-cap biotech. But the direction of travel is downward. Positions fell roughly 2% over the past week to 18.1 million shares, and the borrow market offers no sign of stress: cost to borrow is below half a percent, and availability is at 775% of outstanding short interest, meaning there are nearly eight shares available to lend for every one already borrowed. That is loose by any measure. The ORTEX short score sits at 67, broadly consistent over the past two weeks, confirming that the short-side pressure is neither escalating nor collapsing. Options traders are even less defensive than usual: the put/call ratio of 0.25 is below its 20-day average of 0.29, almost the opposite of what you might expect given the month's price decline.

The Street's official stance is hold, but the underlying analyst mix is considerably more constructive than that label implies. Four firms with active Buy ratings carried targets between $40 and $62 when they last updated, most of those upgrades coming in the May to August window. JP Morgan, the most recent major mover, lifted its target to $50 in early August while keeping an Overweight rating. Goldman Sachs sits at Neutral with a $32 target, essentially at the current price. The bull case centres on IMVT-1402, the company's FcRn inhibitor, and upcoming Phase 2 readouts in Graves' disease and myasthenia gravis. Bears point to the statistical structure of the ongoing study: strong Period 1 efficacy could make the Period 2 threshold harder to clear. Roivant Sciences controls 54.9% of the shares and has filed a Schedule 13D, meaning it is on the SEC register as an active holder rather than a passive one. That concentrated ownership compresses the effective float and means any significant institutional move lands harder than the market cap alone suggests.

The insider record over the past 90 days adds texture. The net position across all trades is a disposal of roughly 32,000 shares for a net value of around $1.2 million. Most of that reflects a cluster of small open-market sales by the CTO and COO at prices between $28.94 and $32.06, executed without a pre-arranged 10b5-1 plan. The CEO's activity in early October is less straightforward: he exercised options and received shares worth $1.3 million at the exercise price, then simultaneously disposed of a larger block at market prices, a routine equity-compensation mechanics pattern rather than a directional bet. The pattern across the broader insider group is consistent selling at prices above current levels, which tells you the stock has continued to fall through transactions rather than that insiders are bearish on the clinical outlook.

The next earnings event is November 6. The two most recent post-results moves were modest: a 2% decline after the September 2026 print and a fractional gain in August. With a short score in the upper 60s, short interest above 10% of float, and the stock down sharply from where insiders were selling just three weeks ago, the more relevant question into that date is whether the clinical data calendar before or around the print produces a catalyst, because the stock price itself has already moved a long way without one.